<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3064">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767701</url>
  </required_header>
  <id_info>
    <org_study_id>008717QM</org_study_id>
    <secondary_id>2012-004847-61</secondary_id>
    <nct_id>NCT01767701</nct_id>
  </id_info>
  <brief_title>Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis</brief_title>
  <acronym>INSPIRE</acronym>
  <official_title>A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether raltegravir is effective in preventing
      progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced
      MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is accumulating research evidence that Human Endogenous Retrovirus (HERV) and herpes
      viruses (in particular Epstein-Barr Virus) are involved in the pathogenesis of multiple
      sclerosis. People with active MS have higher levels of HERVs than people either without MS
      or who have other neurological conditions. It has been shown that HERVs may produce
      neurotoxic proteins/antigens associated with MS activity and disease progression. This is
      the first clinical trial investigating the hypothesis that the antiretroviral drug
      raltegravir may suppress HERV activity and ameliorate progression of relapsing remitting MS.
      Raltegravir is an integrase inhibitor which blocks retroviral replication. A recent
      experimental study suggests that raltegravir may also be active against herpes viruses.

      Eligible participants (see Inclusion/Exclusion Criteria) will be observed for 3 months
      having monthly brain Gadolinium enhanced MRIs and blood/urine/saliva sampling (baseline).
      Then they will be treated with raltegravir (one 400mg pill  taken twice a day) for 3 months.
      During treatment period participants will continue to have monthly MRIs and
      blood/saliva/urine sampling. Participants will have monthly clinical and neurological
      examinations and they will complete questionnaires assessing response to treatment.
      Participants will have screening and study visits at The Royal London Hospital, Whitechapel.
      Monthly MRIs will be performed at the Institute of Neurology at Queens Square, London.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The number of new or recurrent Gd-enhancing lesions that appear on brain T1-weighted MRI</measure>
    <time_frame>Baseline and monthly until month 6 post baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The cumulative number of new or enlarging T2 weighted lesions on brain MRI</measure>
    <time_frame>Baseline and monthly for 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on Multiple Sclerosis Functional Composite (MSFC)</measure>
    <time_frame>Baseline and monthly until month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Kurtzke Extended Disability Status Scale (EDSS) score</measure>
    <time_frame>Baseline and monthly to month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of Gd-T1 enhancing lesions</measure>
    <time_frame>At Baseline and monthly for 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with scans free from enhancing lesions in Raltegravir treated subjects vs. baseline</measure>
    <time_frame>At baseline and monthly for 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Continuously throughout the study</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This outcome will be assessed by blood, urine and saliva sampling; collection of patient reported symptoms and neurological and physical exams.</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>Continuously throught the study</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This outcome will be assessed by blood, urine and saliva sampling; collection of patient reported symptoms and neurological and physical exams.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible patients will complete a 3 months observation period (no medications) followed by 3 months on treatment period. During the treatment period patients will be treated with open label raltegravir 400mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400mg twice daily for 3 months</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18-55 years of age.

          -  Diagnosis of MS, according to the revised McDonald Criteria 2010.

          -  EDSS score of 0-6.0 inclusive.

          -  Documented at least one relapse within the past 12 months or at least one Gd-enhanced
             lesion on the brain MRI detected within 3 months prior to screening date

          -  Gd-enhanced lesion on screening MRI (if MRI not used to meet screening criteria
             above).

          -  Female patients of childbearing potential will be expected to be on appropriate
             contraception (hormonal or barrier method of birth control; abstinence) from time of
             consent until 6 weeks after treatment discontinuation. (the repeated administration
             of gadolinium and MRI are not recommended during pregnancy). NOTE:  Subjects are
             considered not of child bearing potential if they are surgically sterile (they have
             undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or
             they are postmenopausal.

          -  Females of childbearing potential must have a negative urine pregnancy test prior to
             every MRI scan/ within 7 days prior to being registered for protocol therapy.

          -  Must give written informed consent and authorize the release and use of protected
             health information, as required by local law.

          -  Able and willing to undergo blood, saliva and urine sampling at regular intervals as
             defined by the protocol.

          -  Able and willing to receive Gadolinium enhanced MRI's at regular intervals as defined
             by the protocol.

          -  Able to comply with study requirements.

        Exclusion Criteria:

          -  Pregnant or breastfeeding or unwilling to use contraception.

          -  Treatment with immunosuppressive, immunomodulatory or experimental treatments within
             the last 6 months of enrolment in the study, but excluding pulsed intravenous or oral
             steroids for treatment of MS relapse.

          -  No pulsed intravenous or oral steroids in the 30 days preceding the baseline
             assessment.

          -  Patients presenting with medical disorder deemed severe or unstable by the CI such as
             poorly controlled diabetes or arterial hypertension, severe cardiac insufficiency,
             unstable ischemic heart disease, abnormal liver function tests (&gt;2.5 times ULN) and
             abnormal complete blood count (in particular leukopenia, as defined by a lymphocyte
             count &lt;500, neutrophil &lt;1.5 or platelet count &lt; 100,  or thrombocytopenia &lt; 1.5 LLN),
             or any medical condition which, in the opinion of the chief investigator, would pose
             additional risk to the patient.

          -  Presence of human immunodeficiency virus antibodies.

          -  Patients receiving proton pump inhibitors (e.g. omeprazole/esomeprazole)

          -  Patients with active hepatitis B or/and C with liver function tests &gt;2.5 times ULN

          -  Exposure to any other investigational drug within 30 days of enrolment in the study.

          -  Prior history of malignancy unless an exception is granted by the Chief Investigator.

          -  History of uncontrolled drug or alcohol abuse within 6 months prior to enrolment into
             the study.

          -  Patients treated with Rifampicin in past four weeks.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Gold, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gavin Giovannoni</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ailsa Weatherall</last_name>
    <phone>02078827181</phone>
    <email>ailsa.weatherall@bartshealth.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ailsa Weatherall</last_name>
      <phone>02078827181</phone>
      <email>ailsa.weatherall@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Julian Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Calado-Marta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hubert Maruszak</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klaus Schmierer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gavin Giovannoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ute-Christiane Meier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tove Christensen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://multiple-sclerosis-research.blogspot.co.uk/p/charcot-project.html</url>
    <description>The Charcot Project is an initiative to promote research and the dissemination of information around the hypothesis that multiple sclerosis is caused by a virus.</description>
  </link>
  <reference>
    <citation>Christensen T. HERVs in neuropathogenesis. J Neuroimmune Pharmacol. 2010 Sep;5(3):326-35. doi: 10.1007/s11481-010-9214-y. Epub 2010 Apr 27. Review.</citation>
    <PMID>20422298</PMID>
  </reference>
  <reference>
    <citation>Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler. 2012 Dec;18(12):1721-36. doi: 10.1177/1352458512441381. Epub 2012 Mar 28.</citation>
    <PMID>22457345</PMID>
  </reference>
  <reference>
    <citation>Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K, Miller DH, Giovannoni G. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009 Jul 7;73(1):32-8. doi: 10.1212/WNL.0b013e3181aa29fe. Epub 2009 May 20.</citation>
    <PMID>19458321</PMID>
  </reference>
  <reference>
    <citation>Nadal M, Mas PJ, Blanco AG, Arnan C, Sol√† M, Hart DJ, Coll M. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16078-83. doi: 10.1073/pnas.1007144107. Epub 2010 Aug 30. Erratum in: Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):17059. Mas, Phillipe J [corrected to Mas, Philippe J].</citation>
    <PMID>20805464</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 12, 2013</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Mary University of London</investigator_affiliation>
    <investigator_full_name>Gavin Giovannoni</investigator_full_name>
    <investigator_title>Professor Gavin Giovannoni, Chair of Neurology</investigator_title>
  </responsible_party>
  <keyword>raltegravir</keyword>
  <keyword>MS</keyword>
  <keyword>RRMS</keyword>
  <keyword>Charcot Project</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
